Introduction
A gastroenterologist is a professional who diagnoses stomach and digestive problems. An individual can only focus on his daily chores if his health is fit and fine. Nowadays, individuals suffer from various digestive issues, and if these symptoms are ignored, they can lead to a severe problem. A professional gastroenterologist possesses a variety of…
Shots:
Ahsan spoke about the US FDA acceptance for Priority Review of sBLAs for PADCEV and KEYTRUDA to treat patients with LA/mUC who are not eligible to receive cisplatin-containing CT
He also talked about the study design and outcomes from the P-Ib/II (EV-103) clinical trial that supported the sBLA. The results from Dose Escalation/Cohort A…
Shots:
The US FDA approved 5 NDAs and 2 BLA in July 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 76 novel products in 2023
In July 2023, the major highlights drugs were Beyfortus (nirsevimab) approval for the prevention of RSV lower respiratory tract disease in…
Shots:
The US FDA approved 5 NDAs and 5 BLA in February 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 19 novel products in 2023
In February 2023, the major highlights drugs were, Tezspire (tezepelumab) approval for severe asthma, Altuviiio for hemophilia A
PharmaShots has compiled…
Shots:
With the healthcare sector moving ahead with its technological advances, there is still an unexplored section in therapeutics that requires much more attention. Through innovations, life science companies have evolved to make breakthrough discoveries in many focus areas, but when it comes to the rare disease segment, all our endeavors seem to be bleak…
Shots:
Roche was the top dealmaker in 2022 with a completion of 31 deals with multiple pharma, biotech companies, and universities for a total deal value of $13.55B
The highest deal was secured by Roche under its development and commercialization collaboration with Poseida for the R&D of multiple existing and novel cell therapies for the…
The US FDA approved 1 NDAs and 2 BLA in October 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 66 novel products in 2022
In October 2022, the major highlights drugs were Tecvayli’s approval for relapsed or refractory multiple myeloma, Furoscix for congestion in chronic heart…
Active Ingredient: bictegravir, emtricitabine, and tenofovir alafenamide
Strength: 50 mg of BIC, 200 mg of FTC, and 25 mg of TAF/ 30 mg of BIC, 120 mg of FTC, and 15 mg of TAF
Dosage Form: Tablet
Mechanism of Action: HIV reverse transcriptase inhibitors
First Approval: US (07 Feb 2018), EU (25 Jun 2018)
Revenue1
Gilead's HIV drug, Biktarvy has…
Active Ingredient: Aflibercept
Strength: 2 mg (0.05 mL)
Dosage Form: Injection (intravitreal)
Mechanism of Action: VEGF-A and PlGF inhibitors
First Approval: US (18 Nov 2011), EU (27 Nov 2012)
Revenue1
EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…
Active Ingredients: Ustekinumab
Strength: 45 mg/0.5 mL or 90 mg/mL (SC), 130 mg/26 mL (IV)
Dosage Form: Injection
Mechanism of Action: Interleukin 12 & 23 inhibitor
First Approval: US (25 Sep, 2009), EU (16 Jan, 2009)
Revenue1
Stelara is the leading blockbuster drug of Johnson & Johnson. Stelara contributed 9.7% of the Company's total revenues for 2021. Stelara up took…

